Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines

dc.contributor.authorLuczkowiak, Joanna
dc.contributor.authorRivas, Gonzalo
dc.contributor.authorLabiod, Nuria
dc.contributor.authorLasala, Fátima
dc.contributor.authorRolo, Marta
dc.contributor.authorLora-Tamayo Morillo-Velarde, Jaime
dc.contributor.authorMancheno Losa, Mikel
dc.contributor.authorRial Crestelo, David
dc.contributor.authorPérez Rivilla, José Alfredo
dc.contributor.authorFolgueira López, María Dolores
dc.contributor.authorDelgado Vázquez, Rafael
dc.date.accessioned2023-06-22T12:30:09Z
dc.date.available2023-06-22T12:30:09Z
dc.date.issued2023-11-01
dc.descriptionCRUE-CSIC (Acuerdos Transformativos 2022)
dc.description.abstractWe have measured the humoral response to messenger RNA (mRNA) vaccines in COVID-19 naïve and convalescent individuals. Third doses of mRNA COVID-19 vaccines induced a significant increase in potency and breadth of neutralization against SARS-CoV-2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross-neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID-19 convalescents except for BA.4/5. Avidity of RBD-binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS-CoV-2 sequences are required to induce high avidity cross-neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipUnion Europea. Horizonte Europa
dc.description.sponsorshipUnión Europea. Horizonte 2020
dc.description.sponsorshipInstituto de Salud Carlos III (ISCIII)
dc.description.sponsorshipFundación Caixa‐Health Research
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/75687
dc.identifier.doi10.1002/jmv.28268
dc.identifier.issn0146-6615
dc.identifier.officialurlhttps://doi.org/10.1002/jmv.28268
dc.identifier.urihttps://hdl.handle.net/20.500.14352/72699
dc.issue.number1
dc.journal.titleJournal of Medical Virology
dc.language.isoeng
dc.publisherWiley
dc.relation.projectIDEPIC-CROWN-2 (101046084)
dc.relation.projectIDVIRUSCAN (731868);
dc.relation.projectIDFIS PI1801007 and PI2100989
dc.relation.projectIDProject StopEbola HR18‐ 00469
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subject.keywordavidity
dc.subject.keywordCOVID‐19
dc.subject.keywordneutralizing antibodies
dc.subject.keywordOmicron
dc.subject.keywordSARS‐CoV‐2
dc.subject.keywordvaccines
dc.subject.keywordvariants of concern
dc.subject.ucmInmunología
dc.subject.unesco2412 Inmunología
dc.titleCross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
dc.typejournal article
dc.volume.number95
dspace.entity.typePublication
relation.isAuthorOfPublication1f7ba99e-b586-4ff0-9bcd-83e6a91729e4
relation.isAuthorOfPublicationc7667657-f914-4b7b-af19-64a705bc0ccd
relation.isAuthorOfPublicatione60f9b15-34c9-4353-a672-54926c89eec4
relation.isAuthorOfPublication6612f6f9-e6aa-4eb2-bcf2-158a46babc21
relation.isAuthorOfPublication.latestForDiscovery1f7ba99e-b586-4ff0-9bcd-83e6a91729e4

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Journal of Medical Virology - 2022 - Luczkowiak - Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated.pdf
Size:
769.64 KB
Format:
Adobe Portable Document Format

Collections